Sale of Future Royalties - Narrative (Details) - USD ($)	1 Months Ended			3 Months Ended		9 Months Ended
	May 31, 2024	Sep. 30, 2022	Oct. 31, 2021	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Jan. 01, 2021
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue				$ 30,017,000	$ 3,318,000	$ 48,167,000	$ 8,152,000
Liability related to sale of future royalties				350,564,000		350,564,000		$ 310,807,000
Non-cash interest expense				$ 15,413,000	4,431,000	32,683,000	13,125,000
Jemperli Royalty Monetization Agreement
Liabilities Related To Sale Of Future Royalties [Line Items]
Issuance costs related to the sale of future royalties						$ 103,000
Net of proceeds			$ 299,500,000
Effective interest rate				20.30%		20.30%
Non-cash interest expense and amortization of issuance costs				$ 15,200,000	4,200,000	$ 32,000,000	12,400,000
Non-cash interest expense						31,978,000
Jemperli Royalty Monetization Agreement \| Sagard
Liabilities Related To Sale Of Future Royalties [Line Items]
Proceeds from sale of future royalties			250,000,000
Royalties agreement, maximum annual royalty payout capacity			1,000,000,000
Royalties and milestones received				50,300,000		50,300,000
Issuance costs related to the sale of future royalties			400,000
Jemperli Royalty Monetization Agreement \| Sagard \| By the end of 2026
Liabilities Related To Sale Of Future Royalties [Line Items]
Royalties and milestones, agreement amount to be received			600,000,000
Jemperli Royalty Monetization Agreement \| Sagard \| During 2027
Liabilities Related To Sale Of Future Royalties [Line Items]
Royalties and milestones, agreement amount to be received			$ 675,000,000
Jemperli Royalty Monetization Agreement \| GSK
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue				13,800,000	2,500,000	30,100,000	5,800,000
Annual sales milestone threshold						250,000,000
Zejula Royalty Monetization Agreement
Liabilities Related To Sale Of Future Royalties [Line Items]
Issuance costs related to the sale of future royalties		$ 200,000
Net of proceeds		34,800,000
Non-cash interest expense						642,000
Zejula Royalty Monetization Agreement \| GSK
Liabilities Related To Sale Of Future Royalties [Line Items]
Collaboration revenue				1,200,000	800,000	3,100,000	2,400,000
Settlement agreement rate									0.50%
Non-cash interest expense				$ 200,000	$ 200,000	$ 700,000	$ 700,000
Zejula Royalty Monetization Agreement \| DRI Healthcare Trust
Liabilities Related To Sale Of Future Royalties [Line Items]
Proceeds from sale of future royalties		35,000,000
Royalties and milestones, agreement amount to be received		10,000,000
Liability related to sale of future royalties		$ 35,000,000
Jemperli Royalty Monetization Agreement Amendment 1 \| Sagard
Liabilities Related To Sale Of Future Royalties [Line Items]
Proceeds from sale of future royalties	$ 50,000,000
Issuance costs related to the sale of future royalties	$ 100,000